Anasens is a disruptive start-up (deep tech) developing an innovative quantitative and connected molecular detection platform for blood or saliva analysis, at home or at a point of service, in less than 5 minutes. Anasens is pioneering DNA-based electrochemical nanosensors for rapid, point-of-care detection. Their platform enables quantitative detection of biomarkers, drugs, and proteins in saliva or blood within minutes. Anasens increases accessibility to precision medicine by offering lab-quality testing that can be done when and where it matters. The company is supported by academic & industry leadership, multiple grants, and a growing IP portfolio.